Opinion|Videos|May 22, 2025
Essential Patient and Caregiver Education for Tarlatamab Treatment Success
Panelists discuss how education materials for tarlatamab include detailed treatment overviews, potential adverse effects, and monitoring requirements, while emphasizing the importance of ensuring that patients and caregivers fully understand the information and can recognize early signs of adverse reactions.
Advertisement
Episodes in this series
Summary for Physicians:
Education Materials/Resources Provided:
- Treatment overview:
- Detailed explanation of tarlatamab, its purpose, and expected benefits.
- Overview of the administration process and frequency of infusions.
- Potential adverse effects:
- Information on common adverse effects (eg, fever, fatigue) and serious adverse events (eg, cytokine release syndrome).
- Signs and symptoms to watch for, and when to seek immediate medical attention.
- Monitoring requirements:
- Postinfusion monitoring expectations (eg, observation for 1-2 hours after infusion).
- Follow-up appointments and any additional monitoring required.
- Support resources:
- Access to 24/7 nursing support for urgent questions or concerns.
- Contact information for the pharmacy and oncology team.
Challenges:
Ensuring patients and caregivers fully understand the information and know how to recognize early signs of adverse reactions.
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.
Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.
The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Findings from the phase 3 VOLGA trial support the FDA approval of perioperative durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5